CAROLYN FLAHERTY: Open Payments
NPI 1538473731 · W. ISLIP, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,522 in 28 payments from 6 companies in 2025. Trend: 2023 $367 · 2024 $927 · 2025 $1,522
Food & beverage: $1,415Education: $107
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 14 | $415 |
| Otsuka America Pharmaceutical, Inc. | 4 | $376 |
| Teva Pharmaceuticals USA, Inc. | 5 | $352 |
| E.R. Squibb & Sons, L.L.C. | 3 | $137 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $124 |
| Neurocrine BioSciences, Inc. | 1 | $118 |
Products named: ARISTADA, ABILIFY MAINTENA, UZEDY, COBENFY, REXULTI, CAPLYTA, LYBALVI, INGREZZA.
Industry payments across NY — which companies pay providers there.
